loader2
Partner With Us NRI

Indegene Ltd share Price Today

Company details

613.40
689.95
470.10
689.95
6M Return 0.00%
1Y Return 16.43%
Mkt Cap.(Cr) 15,904.21
Volume 7,001,739
Div Yield 0.00%
OI
-
OI Chg %
-
Volume 7,001,739

Open Free Trading Account Online with ICICIDIRECT

Incur '0' Brokerage upto ₹500

Pharmaceuticals company Indegene announced Q1FY25 results:

  • Achieved revenue of Rs 6,765 million in Q1FY25 with growth of 11.4% vs Q1FY24
  • Robust EBITDA growth of 14.5% in Q1FY25 vs Q1FY24
  • Became a zero-debt company 

Manish Gupta, Chairman and CEO, Indegene, said: “In Q1FY25, we achieved revenue growth of 11.4% and robust EBITDA growth of 14.5% vs Q1FY24. We continue to see momentum and growth with our largest client and a few of our Top 20 clients with increased activity and volume levels tracking the larger pipeline of impending new product launches"

“Based on our conversations with our top clients, we anticipate similar momentum across the industry. Further, compared to last year, our pipeline is heathier and the quality of conversations with clients is much better, which gives us confidence about driving robust growth in the medium term.”

Suhas Prabhu, CFO, Indegene, said: “Our Q1FY25 EBITDA margin of 19.6% and PAT margin of 13.0% is an improvement of 50 bps and 170 bps vs Q1FY24. Indegene is now a zero-debt company with repayment of loans, and we anticipate the financial leverage to drive stronger PAT growth going forward”

“Also, we continue to strengthen our technology and automation initiatives, which we believe will have a positive impact on the margin in the future. Further, we anticipate that the EBITDA margin would have a similar trajectory as FY24 with a stronger H2 compared to H1.”

Result PDF

View Other Company Results

Indegene Ltd shares SWOT Analysis

Strengths (6)

  • Rising Net Cash Flow and Cash from Operating activity
  • New 52 week high today
  • Growth in Quarterly Net Profit with increasing Profit Margin (YoY)

Weakness (0)

Data not found

Opportunity (1)

  • High Volume, High Gain

Threats (0)

Data not found

Resistance and support

R1 698.6
R2 732.6
R3 775.2
Pivot

656.02

S1 622.1
S2 579.5
S3 545.5
EMA SMA
587.2
575.8
-
-
577.5
576.6
-
-
Delivery and volume
CLIENT NAME DEAL TYPE ACTION DATE AVG. PRICE QUANTITY EXCHANGE
NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Purchase 2024-05-13 580.4 1387957 NSE
GRT STRATEGIC VENTURES LLP Bulk Purchase 2024-05-13 580.96 1358739 NSE
NK SECURITIES RESEARCH PRIVATE LIMITED Bulk Sell 2024-05-13 580.8 1387957 NSE
Name Category Shares
Manish Gupta PUBLIC 8.97%
Sanjay S Parikh PUBLIC 5.01%
Anand Kiran PUBLIC 2.18%
LLP PUBLIC 2.29%
Aarabhi Partners Consultants Llp PUBLIC 2.11%
Vida Trustees Private Limited PUBLIC 2.34%
Rajesh Bhaskaran Nair PUBLIC 7.13%
Gaurav Kapoor PUBLIC 2.62%
Nadathur Fareast Pte Ltd PUBLIC 22.03%
Ca Dawn Investments PUBLIC 14.52%
Bpc Genesis Fund I Spv Ltd PUBLIC 6.29%
Bpc Genesis Fund I A Spv Ltd PUBLIC 3.26%
Sycamore Philanthropy (Ptc) As Trustee O PUBLIC 1.44%

FINANCIALS

Sales
Operating Profit
Profit after Tax
Equity
Reserves and Surplus
Debt
Sales
Operating Profit
Profit after Tax
PE
Debt/Equity
P BV

Indegene Ltd Stocks COMPARISON

Financials( in Cr) Indegene Ltd Apollo Hospitals Enterprise Ltd Max Healthcare Institute Ltd Fortis Healthcare Ltd Syngene International Ltd
Price 664.70 6,906.80 898.55 546.80 899.65
% Change 9.18 -0.40 1.47 -2.56 -0.77
Mcap Cr 15,904.21 99,309.42 87,331.15 41,281.10 36,214.24
Revenue TTM Cr 2,589.60 7,273.80 5,704.20 7,175.67 3,488.60
Net Profit TTM Cr 336.70 1,010.50 1,057.64 645.22 510.00
PE TTM 44.88 95.90 82.92 64.36 75.95
1 Year Return 16.43 38.57 51.16 63.30 11.38
ROCE 27.00 15.48 14.96 9.65 13.56
ROE 27.01 13.81 13.37 7.81 12.95
INSIDER & INSTITUTIONAL ACTIVITY

Equity Capital: 1,429.10 Cr FV: 2.00

Period MF Net Purchase / (sold) FII Net
LAST 1M 21,795.20 31,732.91
LAST 3M 82,219.63 37,844.71
LAST 6M 195,814.55 51,713.96
LAST 12M 324,182.79 93,986.84
Indegene Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Sep 04, 2024 l NSE Announcement

Indegene Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Sep 03, 2024 l NSE Announcement

Indegene Limited - Analysts/Institutional Investor Meet/Con. Call Updates

Sep 02, 2024 l NSE Announcement

Date Action Type Ratio
No data found

Indegene Ltd Information

Stock PE (TTM)
44.88
Promoter Holding
0%
Book Value
91.532
ROCE
27%
ROE
27.01%
Description
  • Indegene Ltd was incorporated as `Indegene Lifesystems Private Limited` at Ahmedabad, Gujarat, as a Private Limited Company, dated October 16, 1998 at Ahmedabad. Subsequently, name of the Company was changed to `Indegene Private Limited` and a fresh Certificate of Incorporation was issued by the Registrar of Companies, Maharashtra at Mumbai on May 26, 2016. Thereafter, Company converted to a Public Company with change in name to `Indegene Limited` and a fresh certificate of incorporation was issued to Company by RoC, on November 17, 2022. The Company is a "digital-first" commercialization company focused exclusively on the global life sciences industry. Their solutions enable biopharmaceutical, emerging biotech and medical devices companies develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner. Their portfolio of solutions cover all aspects of commercial, medical, regulatory and R&D operations of life sciences companies. Their Enterprise Commercial Solutions (ECS) involve assisting life sciences companies with their digital marketing operations. Omnichannel Activation solutions help life sciences companies leverage a "digital first" approach for optimizing the last-mile promotion of biopharmaceutical products and medical devices to HCPs across multiple channels. Under Enterprise Medical Solutions, the Company establish centers of excellence (CoEs) to consolidate large scale regulatory and medical operations for their clients. Apart from these, the Company offer Enterprise Clinical Solutions and consultancy services, which help drive efficiencies in the drug discovery and clinical trial operations of life sciences companies. It bring in their expertise in data management and analytics in helping biopharmaceutical companies seamlessly handle and analyze multiple sources of data during clinical trials and build a case for regulatory approvals. In 2016, the Company acquired Encima Group, Inc. in the United States, a company which provided marketing analytics and campaign execution solutions to several large life sciences companies. In 2019, it acquired a minority stake in DT Associates Research and Consulting Services Limited, a digital transformation and client experience consulting firm in UK, to expand their strategic consulting capabilities. In December 2020, it acquired a majority stake in DT Associates Limited. On 8 December, 2021 the Company has demerged its commercial software business pursuant to a Scheme of Arrangement for transfer of the Demerged Business to OT Services India Private Limited (Resulting Company), approved by the National Company Law Tribunal, Bengaluru Bench with Appointed Date, i.e., October 1, 2020, which became effective on December 30, 2021. The Company acquired Cult Health, a full-service healthcare marketing agency for several life sciences brands, through its subsidiary, ILSL Holdings, Inc. on October 12, 2022. The Company is planning to raise capital from Public by raising Rs 950 crores through fresh issue and 36,291,497 Equity Shares through Offer For Sale.

Registered Address

Aspen Block G4 3rd Flr Manyata, Embassy Busi. Park Nagawara, Bengaluru, Karnataka, 560045

Tel : 91-80-4674 4567/+91-80-4644 7777
Email : compliance.officer:indegene.com
Website : http://www.indegene.com
Registrar

Link Intime India Pvt Ltd

AGM Date (Month) :
Face Value Equity Shares : 2
Market Lot Equity Shares : 1
BSE Code : 544172
NSE Code : INDGN
Book Closure Date (Month) :
BSE Group : B
ISIN : INE065X01017

FAQ’s on Indegene Ltd Shares

You can buy Indegene Ltd shares through a brokerage firm. ICICIdirect is a registered broker through which you can place orders to buy Indegene Ltd Share.

Company share prices and volatile and keep changing according to the market conditions. As of Sep 06, 2024 04:03 PM the closing price of Indegene Ltd was Rs.664.70.

The latest PE ratio of Indegene Ltd as of Sep 06, 2024 04:03 PM is 44.88

The latest PB ratio of Indegene Ltd as of Sep 06, 2024 04:03 PM is 0.14

The 52-week high of Indegene Ltd share price is Rs. 689.95 while the 52-week low is Rs. 470.10

Market capitalization or market cap is determined by multiplying the current market price of a company's shares with the total number of shares outstanding. As of Sep 06, 2024 04:03 PM, the market cap of Indegene Ltd stood at Rs. 15,904.21 Cr.

Download App

Download Our App

Play Store App Store
market app